To be honest this does look like solid competition. See also their website. They also have QIDP and they have Fast Track approval as well and have just begun phase 2b trials. Interestingly they achieved QIDP in 2015, so seem to be moving very slowly for some reason.
Efficacy also looks solid. Note all the other indications they are looking to address in their product pipeline.
Hopefully we come up with as good or better trial results quickly with our excellent safety profile as a plus.
Aside from being a competitor, if nothing else this helps to validate the potential market and the overall approach we are taking in the anti microbial space.
BOT - Anything but charting, page-1445
-
- There are more pages in this discussion • 7,630 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.8¢ | $1.949M | 5.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2985 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 420471 | 4 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |